70 related articles for article (PubMed ID: 8930211)
1. Ribavirin potentiates the efficacy and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model.
Harvie P; Omar RF; Dusserre N; Lansac N; Désormeaux A; Gourde P; Simard M; Tremblay M; Beauchamp D; Bergeron MG
J Pharmacol Exp Ther; 1996 Nov; 279(2):1009-17. PubMed ID: 8930211
[TBL] [Abstract][Full Text] [Related]
2. Antiviral efficacy and toxicity of ribavirin and foscarnet each given alone or in combination in the murine AIDS model.
Omar RF; Harvie P; Gourde P; Désormeaux A; Tremblay M; Beauchamp D; Bergeron MG
Toxicol Appl Pharmacol; 1997 Mar; 143(1):140-51. PubMed ID: 9073602
[TBL] [Abstract][Full Text] [Related]
3. Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model.
Harvie P; Omar RF; Dusserre N; Désormeaux A; Gourde P; Tremblay M; Beauchamp D; Bergeron MG
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):451-61. PubMed ID: 8757421
[TBL] [Abstract][Full Text] [Related]
4. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
[TBL] [Abstract][Full Text] [Related]
5. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Mayhew C; Oakley O; Piper J; Hughes NK; Phillips J; Birch NJ; Elford HL; Gallicchio VS
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1019-29. PubMed ID: 9449534
[TBL] [Abstract][Full Text] [Related]
6. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.
Klein MB; Campeol N; Lalonde RG; Brenner B; Wainberg MA
AIDS; 2003 May; 17(7):1001-8. PubMed ID: 12700449
[TBL] [Abstract][Full Text] [Related]
7. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
[TBL] [Abstract][Full Text] [Related]
8. In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
Sumpter LR; Inayat MS; Yost EE; Duvall W; Hagan E; Mayhew CN; Elford HL; Gallicchio VS
Antiviral Res; 2004 Jun; 62(3):111-20. PubMed ID: 15130534
[TBL] [Abstract][Full Text] [Related]
9. 2'3'-Dideoxyinosine inhibits the humoral immune response in female B6C3F1 mice by targeting the B lymphocyte.
Phillips KE; Munson AE
Toxicol Appl Pharmacol; 1997 Aug; 145(2):260-7. PubMed ID: 9266798
[TBL] [Abstract][Full Text] [Related]
10. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment.
Witt KL; Tice RR; Wolfe GW; Bishop JB
Environ Mol Mutagen; 2004; 44(4):321-8. PubMed ID: 15476197
[TBL] [Abstract][Full Text] [Related]
11. Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model.
Fraternale A; Casabianca A; Orlandi C; Cerasi A; Chiarantini L; Brandi G; Magnani M
Antiviral Res; 2002 Dec; 56(3):263-72. PubMed ID: 12406509
[TBL] [Abstract][Full Text] [Related]
12. Prenatal developmental toxicity evaluation of 2',3'-dideoxyinosine (ddI) and 2',3'-didehydro-3'-deoxythymidine (d4T) co-administered to Swiss Albino (CD-1) mice.
Price CJ; George JD; Marr MC; Myers CB; Bieler GS; Williams RL; Jahnke GD
Birth Defects Res B Dev Reprod Toxicol; 2006 Jun; 77(3):207-15. PubMed ID: 16767756
[TBL] [Abstract][Full Text] [Related]
13. AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
James JS
AIDS Treat News; 1996 Apr; (no 244):6. PubMed ID: 11363307
[TBL] [Abstract][Full Text] [Related]
14. Combining d4T/ddI looks promising.
Posit Aware; 1996; 7(1):7. PubMed ID: 11363129
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of murine AIDS (MAIDS) development in C57BL/6J mice by tyrphostin AG-1387.
Sklan EH; Gazit A; Priel E
Virology; 2000 Dec; 278(1):95-102. PubMed ID: 11112485
[TBL] [Abstract][Full Text] [Related]
16. Beyond hydroxyurea.
Smart T
GMHC Treat Issues; 1995 Sep; 9(9):5. PubMed ID: 11362909
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS.
Magnani M; Fraternale A; Casabianca A; Schiavano GF; Chiarantini L; Palamara AT; Ciriolo MR; Rotilio G; Garaci E
AIDS Res Hum Retroviruses; 1997 Sep; 13(13):1093-9. PubMed ID: 9282814
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.
Meng Q; Su T; O'Neill JP; Walker VE
Environ Mol Mutagen; 2002; 39(4):282-95. PubMed ID: 12112380
[TBL] [Abstract][Full Text] [Related]
19. In vivo toxicity of foscarnet and zidovudine given alone or in combination.
Omar RF; Gourde P; Désormeaux A; Tremblay M; Beauchamp D; Bergeron MG
Toxicol Appl Pharmacol; 1996 Aug; 139(2):324-32. PubMed ID: 8806849
[TBL] [Abstract][Full Text] [Related]
20. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
